A new biodegradable stent in bilio-pancreatic diseases: a prospective multi-center feasibility study

• Enrique Pérez-Cuadrado Robles ^[2] ; Sundeep Lakhtakia ^[3] ; Hairol Othman ^[1] ; Harsh Vardhan Tewethia ^[3] ; Nur Yaacob ^[1] ; Razman Jarmin ^[1] ; Zahiah Mohamed ^[1] ; Elsa Jasmin Roslan ^[1] ; Guillaume Perrod ^[2] ; Hédi Benosman ^[2] ; Christophe Cellier ^[2] ; Gabriel Rahmi ^[2] ; Nageshwar Reddy ^[3]
  1. [1] National University of Malaysia

     National University of Malaysia

     Malasia

     
  2. [2] Hôpital Européen Georges Pompidou. Paris, France
  3. [3] AIG Hospitals. Hyderabad, India

  Mostrar afiliaciones +
• Localización: Revista Española de Enfermedades Digestivas, ISSN-e 2340-4167, ISSN 1130-0108, Vol. 114, Nº. 9, 2022, págs. 529-533
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Introduction: biodegradable stents of various designs are reportedly used in pancreato-biliary conditions with promising results. Their major advantage is the avoidance of repeat endoscopic procedure for stent removal, thereby reducing overall costs and endoscopic retrograde cholangiopancreatography (ERCP) associated adverse events. The aim of the study was to evaluate the feasibility and safety of a new biodegradable stent in patients with pancreato-biliary diseases. Methods: a prospective multicenter pilot study was performed. All consecutive patients ≥ 18 years old who underwent biliary or pancreatic stenting using the new biodegradable Archimedes stent were included in the study. There were three biodegradation profiles. Technical and clinical success and feasibility and safety were assessed during a pre-established follow-up schedule. Results: fifty-three patients (mean age: 48.54 ± 19.29, 66 % male) with biliary (n = 29, 54.7 %) or pancreatic (n = 24, 45.3 %) indications were included. The distribution of stents used according to degradation properties were as follows: fast (n = 11, 20.8 %), medium (n = 16, 30.2 %) and slow (n = 26, 49.1 %). The technical and clinical success were 100 % and 77.8 %, respectively. Thirty-five patients were followed for a median of 26 weeks (range: 4-56, 66 %). There were nine procedure-related adverse events (17 %), all mild, including one uneventful stent-related event (external migration). Conclusion: the biodegradable Archimedes stent placement is feasible and safe in pancreato-biliary diseases.